Abstract

Author(s)

Scott Clark

Affiliations

University of Adelaide, CALHN

Introduction

People living with mental illness experience substantially poorer physical health and reduced life expectancy—up to 15 years shorter than the general population. Chronic diseases such as cardiovascular disease, diabetes, cancer, and respiratory illness account for ten times more premature deaths than suicide in this group. The burden is compounded by modifiable behavioural risk factors including smoking, obesity, and physical inactivity, alongside inequities in access to preventive health services. Furthermore, psychotropic medications, especially antipsychotics, contribute to metabolic disturbances, necessitating improved cardiometabolic monitoring and personalised treatment approaches.

Method

Recent translational research has integrated epidemiological, clinical, and genomic data to investigate the interplay between mental illness and physical health outcomes. Large-scale analyses, including pathway studies, have examined shared genetic loci between mood disorders and cardiometabolic conditions. Concurrently, interventional trials have been designed to test whether metabolic agents—metformin, GLP-1 agonists, and statins—can improve both physical and psychiatric outcomes in individuals with severe mental illness.

Results & findings

Genetic and molecular findings reveal significant overlap in biological pathways—including AMPK, leptin, circadian rhythm, and dopaminergic signalling—linking cardiometabolic and mood disorders. Early clinical trial data suggest that targeting metabolic dysfunction may yield dual benefits: reducing cardiovascular risk and enhancing mood stability. Preliminary outcomes from these studies indicate that pharmacological interventions, when combined with structured lifestyle and monitoring programs, improve both metabolic parameters and depressive symptomatology.

Discussion

These findings underscore the urgent need for integrated care models that unite psychiatry, primary care, and cardiology. Addressing cardiovascular morbidity in mental illness requires coordinated attention to pharmacogenomics, lifestyle modification, and equitable access to preventive and therapeutic services. Bridging the divide between mental and physical health represents a critical public health priority, with potential to significantly reduce premature mortality and improve holistic wellbeing for people with mental disorders.